Photoelectrochemical Assay Based on SnO₂/BiOBr p–n Heterojunction for Ultrasensitive DNA Detection

Herein, a photoelectrochemical (PEC) assay was designed for a highly sensitive DNA determination relying upon the SnO2/BiOBr p–n heterojunction as a photoactive material and SiO2 as a signal quencher. Compared with most traditional heterojunctions, the SnO2/BiOBr p–n heterostructure not only lessened the recombination of the photogenerated electron–hole pairs but also promoted the light-harvesting in the ultraviolet–visible (UV–vis) region, leading to further enhanced photoelectric conversion efficiency and photocurrent, which demonstrated 12.1-fold and 6.4-fold increments versus those of pure SnO2 and BiOBr, respectively. Additionally, the limited quantity of target DNA (a fragment of p53 gene) could be transformed into abundant output DNA–SiO2 by employing the Nt·BstNBI enzyme-assisted signal amplification procedure, leading to a highly improved detection sensitivity of the biosensor. Then, output DNA–SiO2 hybridized with the capture DNA anchored on the modified electrode surface, remarkably diminishing the PEC signal and thus achieving sensitive DNA determination. The elaborated PEC biosensor demonstrated outstanding performance within the linear range between 0.5 fM and 5 nM and a low limit of detection down to 0.18 fM, paving a new way for fabricating heterojunction with exceptional photoactive performance and demonstrating the enormous potential for detecting multitudinous biomarkers in bioanalysis and clinical therapy

Image_2_Evolving trends and burden of iron deficiency among children, 1990–2019: a systematic analysis for the global burden of disease study 2019.TIF

ObjectivesWe aimed to provide a timely, comprehensive, and reliable assessment of the burden of iron deficiency (ID) in children between 1990 and 2019 at the global, regional, and national levels to inform policymakers in developing locally appropriate health policies.MethodsData related to ID among children younger than 15 years old were analyzed by sex, age, year, socio-demographic index (SDI), and location according to the Global Burden of Disease Study 2019 (GBD 2019). Age-standardized rates were used to compare the burden between different regions and countries. Furthermore, the Joinpoint regression model was used to assess temporal trends from 1990 to 2019.ResultsIn 2019, the number of prevalent cases and disability-adjusted life years (DALYs) for ID in children were 391,491,699 and 13,620,231, respectively. The global age-standardized prevalence and DALY rates for childhood ID in 2019 were 20,146.35 (95% confidence interval: 19,407.85 to 20,888.54) and 698.90 (466.54 to 1015.31) per 100,000, respectively. Over the past 30 years, the global prevalence of ID among children has been highest in low-SDI regions, particularly in Western Sub-Saharan Africa, South Asia, and Eastern Sub-Saharan Africa. Since 1990, the prevalence and DALY of ID in children have been declining in most geographic regions. Nationally, Ecuador, China, and Chile have shown the most significant decreases in prevalence. The greatest decline in age-standardized DALY rate was observed in Ecuador, while Burkina Faso experienced the highest increase. Bhutan had the highest prevalence and DALY rates in 2019. On the age level, the prevalence was relatively higher among the ConclusionAlthough the burden of ID in children has been declining, this disease remains a major public health problem, especially in countries with low SDI. Children younger than 5 years of age are an important group for whom targeted measures are needed to reduce the burden of ID.</p

Data_Sheet_1_Evolving trends and burden of iron deficiency among children, 1990–2019: a systematic analysis for the global burden of disease study 2019.docx

ObjectivesWe aimed to provide a timely, comprehensive, and reliable assessment of the burden of iron deficiency (ID) in children between 1990 and 2019 at the global, regional, and national levels to inform policymakers in developing locally appropriate health policies.MethodsData related to ID among children younger than 15 years old were analyzed by sex, age, year, socio-demographic index (SDI), and location according to the Global Burden of Disease Study 2019 (GBD 2019). Age-standardized rates were used to compare the burden between different regions and countries. Furthermore, the Joinpoint regression model was used to assess temporal trends from 1990 to 2019.ResultsIn 2019, the number of prevalent cases and disability-adjusted life years (DALYs) for ID in children were 391,491,699 and 13,620,231, respectively. The global age-standardized prevalence and DALY rates for childhood ID in 2019 were 20,146.35 (95% confidence interval: 19,407.85 to 20,888.54) and 698.90 (466.54 to 1015.31) per 100,000, respectively. Over the past 30 years, the global prevalence of ID among children has been highest in low-SDI regions, particularly in Western Sub-Saharan Africa, South Asia, and Eastern Sub-Saharan Africa. Since 1990, the prevalence and DALY of ID in children have been declining in most geographic regions. Nationally, Ecuador, China, and Chile have shown the most significant decreases in prevalence. The greatest decline in age-standardized DALY rate was observed in Ecuador, while Burkina Faso experienced the highest increase. Bhutan had the highest prevalence and DALY rates in 2019. On the age level, the prevalence was relatively higher among the ConclusionAlthough the burden of ID in children has been declining, this disease remains a major public health problem, especially in countries with low SDI. Children younger than 5 years of age are an important group for whom targeted measures are needed to reduce the burden of ID.</p

Image_1_Evolving trends and burden of iron deficiency among children, 1990–2019: a systematic analysis for the global burden of disease study 2019.TIF

ObjectivesWe aimed to provide a timely, comprehensive, and reliable assessment of the burden of iron deficiency (ID) in children between 1990 and 2019 at the global, regional, and national levels to inform policymakers in developing locally appropriate health policies.MethodsData related to ID among children younger than 15 years old were analyzed by sex, age, year, socio-demographic index (SDI), and location according to the Global Burden of Disease Study 2019 (GBD 2019). Age-standardized rates were used to compare the burden between different regions and countries. Furthermore, the Joinpoint regression model was used to assess temporal trends from 1990 to 2019.ResultsIn 2019, the number of prevalent cases and disability-adjusted life years (DALYs) for ID in children were 391,491,699 and 13,620,231, respectively. The global age-standardized prevalence and DALY rates for childhood ID in 2019 were 20,146.35 (95% confidence interval: 19,407.85 to 20,888.54) and 698.90 (466.54 to 1015.31) per 100,000, respectively. Over the past 30 years, the global prevalence of ID among children has been highest in low-SDI regions, particularly in Western Sub-Saharan Africa, South Asia, and Eastern Sub-Saharan Africa. Since 1990, the prevalence and DALY of ID in children have been declining in most geographic regions. Nationally, Ecuador, China, and Chile have shown the most significant decreases in prevalence. The greatest decline in age-standardized DALY rate was observed in Ecuador, while Burkina Faso experienced the highest increase. Bhutan had the highest prevalence and DALY rates in 2019. On the age level, the prevalence was relatively higher among the ConclusionAlthough the burden of ID in children has been declining, this disease remains a major public health problem, especially in countries with low SDI. Children younger than 5 years of age are an important group for whom targeted measures are needed to reduce the burden of ID.</p

Image_3_Evolving trends and burden of iron deficiency among children, 1990–2019: a systematic analysis for the global burden of disease study 2019.TIF

ObjectivesWe aimed to provide a timely, comprehensive, and reliable assessment of the burden of iron deficiency (ID) in children between 1990 and 2019 at the global, regional, and national levels to inform policymakers in developing locally appropriate health policies.MethodsData related to ID among children younger than 15 years old were analyzed by sex, age, year, socio-demographic index (SDI), and location according to the Global Burden of Disease Study 2019 (GBD 2019). Age-standardized rates were used to compare the burden between different regions and countries. Furthermore, the Joinpoint regression model was used to assess temporal trends from 1990 to 2019.ResultsIn 2019, the number of prevalent cases and disability-adjusted life years (DALYs) for ID in children were 391,491,699 and 13,620,231, respectively. The global age-standardized prevalence and DALY rates for childhood ID in 2019 were 20,146.35 (95% confidence interval: 19,407.85 to 20,888.54) and 698.90 (466.54 to 1015.31) per 100,000, respectively. Over the past 30 years, the global prevalence of ID among children has been highest in low-SDI regions, particularly in Western Sub-Saharan Africa, South Asia, and Eastern Sub-Saharan Africa. Since 1990, the prevalence and DALY of ID in children have been declining in most geographic regions. Nationally, Ecuador, China, and Chile have shown the most significant decreases in prevalence. The greatest decline in age-standardized DALY rate was observed in Ecuador, while Burkina Faso experienced the highest increase. Bhutan had the highest prevalence and DALY rates in 2019. On the age level, the prevalence was relatively higher among the ConclusionAlthough the burden of ID in children has been declining, this disease remains a major public health problem, especially in countries with low SDI. Children younger than 5 years of age are an important group for whom targeted measures are needed to reduce the burden of ID.</p

Additional file 4: of Phenotypical profile and global transcriptomic profile of Hypervirulent Klebsiella pneumoniae due to carbapenemase-encoding plasmid acquisition

Table S2. Comparison of differentially expressed genes in the pLVPK plasmid between the BD2411 and TfpNDM-hvKP isolates (DOC 374 kb

Effects of DCQD on the reduction of cerulein-induced necrosis of AR42J cells.

<p>The cells were pre-treated with increasing concentrations of DCQD (0.00025 g/mL, 0.0005 g/mL, 0.001 g/mL, 0.002 g/mL and 0.004 g/mL) for 30 min and then co-incubated with or without 10⁻⁸ M cerulein for another 0–24 h. (A) Cell viability rate was examined using WST-8 assay. (B) Necrotic cell death rate was assessed by the release rate of LDH. The results are mean ± SE (n = 5) for three independent experiments. *<i>P</i><0.05 versus control group; +<i>P</i><0.05 versus DCQD 0.004 g/mL group; ̂<i>P</i><0.05 versus cerulein group.</p

Additional file 3: of Phenotypical profile and global transcriptomic profile of Hypervirulent Klebsiella pneumoniae due to carbapenemase-encoding plasmid acquisition

Table S1. Susceptibility of K. pnuemoniae BD2411 (WT) and its transformant (TfpNDM-hvKP) (DOC 24 kb

Additional file 5: of Phenotypical profile and global transcriptomic profile of Hypervirulent Klebsiella pneumoniae due to carbapenemase-encoding plasmid acquisition

Table S3. the information and results of the 19 selected genes detected by RNA sequencing and RT-qPCR (DOC 38 kb

DCQD enhanced the acute pancreatitis-associated tissue concentration of NO and iNOS.

<p>Tissue homogenates were collected for NO and iNOS concentration measurement after 48 h treatment. (A) NO concentration (B) and iNOS concentration of sham-operated group, AP group and DCQD-treated group. The results are mean ± SE (n = 6 per group) for three independent experiments. ^#<i>P</i><0.01 versus sham-operated group; ^*<i>P</i><0.01 versus sham-operated group and AP group.</p